HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study.

AbstractOBJECTIVE:
The most common functioning pituitary adenoma is prolactinoma. Patients with medically refractory or residual/recurrent tumors that are not amenable to resection can be treated with stereotactic radiosurgery (SRS). The aim of this multicenter study was to evaluate the role of SRS for treating prolactinomas.
METHODS:
This retrospective study included prolactinomas treated with SRS between 1997 and 2016 at ten institutions. Patients' clinical and treatment parameters were investigated. Patients were considered to be in endocrine remission when they had a normal level of prolactin (PRL) without requiring dopamine agonist medications. Endocrine control was defined as endocrine remission or a controlled PRL level ≤ 30 ng/ml with dopamine agonist therapy. Other outcomes were evaluated including new-onset hormone deficiency, tumor recurrence, and new neurological complications.
RESULTS:
The study cohort comprised 289 patients. The endocrine remission rates were 28%, 41%, and 54% at 3, 5, and 8 years after SRS, respectively. Following SRS, 25% of patients (72/289) had new hormone deficiency. Sixty-three percent of the patients (127/201) with available data attained endocrine control. Three percent of patients (9/269) had a new visual complication after SRS. Five percent of the patients (13/285) were recorded as having tumor progression. A pretreatment PRL level ≤ 270 ng/ml was a predictor of endocrine remission (p = 0.005, adjusted HR 0.487). An increasing margin dose resulted in better endocrine control after SRS (p = 0.033, adjusted OR 1.087).
CONCLUSIONS:
In patients with medically refractory prolactinomas or a residual/recurrent prolactinoma, SRS affords remarkable therapeutic effects in endocrine remission, endocrine control, and tumor control. New-onset hypopituitarism is the most common adverse event.
AuthorsYi-Chieh Hung, Cheng-Chia Lee, Huai-Che Yang, Nasser Mohammed, Kathryn N Kearns, Ahmed M Nabeel, Khaled Abdel Karim, Reem M Emad Eldin, Amr M N El-Shehaby, Wael A Reda, Sameh R Tawadros, Roman Liscak, Jana Jezkova, L Dade Lunsford, Hideyuki Kano, Nathaniel D Sisterson, Roberto Martínez Álvarez, Nuria E Martínez Moreno, Douglas Kondziolka, John G Golfinos, Inga Grills, Andrew Thompson, Hamid Borghei-Razavi, Tanmoy Kumar Maiti, Gene H Barnett, James McInerney, Brad E Zacharia, Zhiyuan Xu, Jason P Sheehan
JournalJournal of neurosurgery (J Neurosurg) Pg. 1-10 (Aug 02 2019) ISSN: 1933-0693 [Electronic] United States
PMID31374549 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: